Using Redox Proteomics to Gain New Insights into Neurodegenerative Disease and Protein Modification
Authors:
- Paula Cadenas-GarridoPCPaula Cadenas-Garrido
- Ailén Schonvandt-AlarcosASAilén Schonvandt-Alarcos
- Lourdes Herrera-QuintanaLHLourdes Herrera-Quintana
- Héctor Vázquez-LorenteHVHéctor Vázquez-Lorente
- Alicia Santamaría-QuilesASAlicia Santamaría-Quiles
- Jon Ruiz de FranciscoJFJon Ruiz de Francisco
- Marina Moya-EscuderoMMMarina Moya-Escudero
- David Martín-OlivaDMDavid Martín-Oliva
- Sandra M. Martín-GuerreroSMSandra M. Martín-Guerrero
- César Rodríguez-SantanaCRCésar Rodríguez-Santana
- Jerónimo Aragón-VelaJerónimo Aragón-Vela
- Julio Plaza-DiazJulio Plaza-Diaz
Open Access
- 20 January 2024
- journal article
- review article
- Published by MDPI AG in Antioxidants
- Vol. 13 (1) , 127
Abstract
Antioxidant defenses in biological systems ensure redox homeostasis, regulating baseline levels of reactive oxygen and nitrogen species (ROS and RNS). Oxidative stress (OS), characterized by a lack of antioxidant defenses or an elevation in ROS and RNS, may cause a modification of biomolecules, ROS being primarily absorbed by proteins. As a result of both genome and environment interactions, proteomics provides complete information about a cell’s proteome, which changes continuously. Besides measuring protein expression levels, proteomics can also be used to identify protein modifications, localizations, the effects of added agents, and the interactions between proteins. Several oxidative processes are frequently used to modify proteins post-translationally, including carbonylation, oxidation of amino acid side chains, glycation, or lipid peroxidation, which produces highly reactive alkenals. Reactive alkenals, such as 4-hydroxy-2-nonenal, are added to cysteine (Cys), lysine (Lys), or histidine (His) residues by a Michael addition, and tyrosine (Tyr) residues are nitrated and Cys residues are nitrosylated by a Michael addition. Oxidative and nitrosative stress have been implicated in many neurodegenerative diseases as a result of oxidative damage to the brain, which may be especially vulnerable due to the large consumption of dioxygen. Therefore, the current methods applied for the detection, identification, and quantification in redox proteomics are of great interest. This review describes the main protein modifications classified as chemical reactions. Finally, we discuss the importance of redox proteomics to health and describe the analytical methods used in redox proteomics.Keywords
This publication has 215 references indexed in Scilit:
- Involvement of Oxidative Stress in Occurrence of Relapses in Multiple Sclerosis: The Spectrum of Oxidatively Modified Serum Proteins Detected by Proteomics and Redox Proteomics AnalysisPLOS ONE, 2013
- Targeting of XJB-5-131 to Mitochondria Suppresses Oxidative DNA Damage and Motor Decline in a Mouse Model of Huntington’s DiseaseCell Reports, 2012
- Protein targets for carbonylation by 4-hydroxy-2-nonenal in rat liver mitochondriaJournal of Proteomics, 2011
- Isotope‐coded dimethyl tagging for differential quantification of posttranslational protein carbonylation by 4‐hydroxy‐2‐nonenal, an end‐product of lipid peroxidationJournal of Mass Spectrometry, 2011
- Chemical probes for analysis of carbonylated proteins: A reviewJournal of Chromatography B, 2011
- Noninvasive quantification of ascorbate and glutathione concentration in the elderly human brainNMR in Biomedicine, 2011
- Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: Implications for Aβ accumulation in AD brainFree Radical Biology and Medicine, 2010
- A targeted mass spectrometry-based approach for the identification and characterization of proteins containing α-aminoadipic and γ-glutamic semialdehyde residuesAnalytical and Bioanalytical Chemistry, 2010
- Redox proteomics identification of 4‐hydroxynonenal‐modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesisProteomics – Clinical Applications, 2009
- Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase IIIAnnals of Neurology, 2009